Diaceutics appears to be navigating the challenging macro backdrop well, with no change to expectations this morning. The orderbook has grown significantly in H1 and there is a strong pipeline of opportunities for H2. An 8th enterprise-wide deal has been signed and the group’s largest individual contract was expanded last week just three months after it started. This is highly reassuring that Diaceutics’ value proposition and strong ROI continues to resonate, even in more uncertain macro times for the group’s core pharma customers. Reiterate Buy / 210p TP.